WAT Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 26.52% compared to Waters's net margin of -22.5%. Waters's return on equity of 43.99% beat Delcath Systems's return on equity of -117.89%.

Waters has a consensus price target of $400.84, signalling upside risk potential of 9.68%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 57.78%. Given that Delcath Systems has higher upside potential than Waters, analysts believe Delcath Systems is more attractive than Waters.

Waters has a beta of 0.997, which suggesting that the stock is 0.345% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.957%.

Waters has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Waters pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Waters quarterly revenues are $872.7M, which are larger than Delcath Systems quarterly revenues of $15.1M. Waters's net income of $231.4M is higher than Delcath Systems's net income of -$3.4M. Notably, Waters's price-to-earnings ratio is 34.12x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Waters is 7.36x versus 11.27x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics has a net margin of 26.52% compared to Waters's net margin of 8.47%. Waters's return on equity of 43.99% beat Quest Diagnostics's return on equity of 12.99%.

Waters has a consensus price target of $400.84, signalling upside risk potential of 9.68%. On the other hand Quest Diagnostics has an analysts' consensus of $177.10 which suggests that it could grow by 6.9%. Given that Waters has higher upside potential than Quest Diagnostics, analysts believe Waters is more attractive than Quest Diagnostics.

Waters has a beta of 0.997, which suggesting that the stock is 0.345% less volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.577%.

Waters has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.81% to investors and pays a quarterly dividend of $0.75 per share. Waters pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Waters quarterly revenues are $872.7M, which are smaller than Quest Diagnostics quarterly revenues of $2.6B. Waters's net income of $231.4M is higher than Quest Diagnostics's net income of $222M. Notably, Waters's price-to-earnings ratio is 34.12x while Quest Diagnostics's PE ratio is 21.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Waters is 7.36x versus 1.90x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Danaher has a net margin of 26.52% compared to Waters's net margin of 16.61%. Waters's return on equity of 43.99% beat Danaher's return on equity of 7.57%.

Waters has a consensus price target of $400.84, signalling upside risk potential of 9.68%. On the other hand Danaher has an analysts' consensus of $266.23 which suggests that it could grow by 25.34%. Given that Danaher has higher upside potential than Waters, analysts believe Danaher is more attractive than Waters.

Waters has a beta of 0.997, which suggesting that the stock is 0.345% less volatile than S&P 500. In comparison Danaher has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.66%.

Waters has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher offers a yield of 0.51% to investors and pays a quarterly dividend of $0.27 per share. Waters pays -- of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Waters quarterly revenues are $872.7M, which are smaller than Danaher quarterly revenues of $6.5B. Waters's net income of $231.4M is lower than Danaher's net income of $1.1B. Notably, Waters's price-to-earnings ratio is 34.12x while Danaher's PE ratio is 40.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Waters is 7.36x versus 6.56x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 26.52% compared to Waters's net margin of 4.31%. Waters's return on equity of 43.99% beat Labcorp Holdings's return on equity of 9.29%.

Waters has a consensus price target of $400.84, signalling upside risk potential of 9.68%. On the other hand Labcorp Holdings has an analysts' consensus of $273.60 which suggests that it could grow by 16.7%. Given that Labcorp Holdings has higher upside potential than Waters, analysts believe Labcorp Holdings is more attractive than Waters.

Waters has a beta of 0.997, which suggesting that the stock is 0.345% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.207%.

Waters has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.23% to investors and pays a quarterly dividend of $0.72 per share. Waters pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Waters quarterly revenues are $872.7M, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Waters's net income of $231.4M is higher than Labcorp Holdings's net income of $143.4M. Notably, Waters's price-to-earnings ratio is 34.12x while Labcorp Holdings's PE ratio is 26.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Waters is 7.36x versus 1.52x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.